Insight

Aug 22, 2024, 14:07

Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects

Elisabetta Bonzano, Radiation Oncologist at San Matteo Polyclinic I.R.C.C.S. Foundation Pavia, shared a post on X about a recent paper by Simona Shaitelman et al. published in International Journal of Radiation Oncology.

“PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects – A Phase II Clinical Trial”

Authors: Simona Shaitelman, Huong Le-Petross, Maria Raso, Isabelle Bedrosian, Elizabeth Mitten et al.

“PRECISE: Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects – A Phase II Clinical Trial.

Stromal TIL increased 6-8 days following completion of boost radiotherapy (median 3.0 (IQR 1.0-6.5) prior to radiotherapy vs. median 5.0 (IQR 1.5-8.0) post-radiotherapy, p=0.0037.
Zero grade ≥ 3 toxicities up to 6 months following boost were experienced.
94% (16/17) patients with 6-month follow-up cosmetic assessment following breast conservation had good-excellent cosmesis by physician assessment.”

Source: Elisabetta Bonzano/X

cancer Elisabetta Bonzano Elizabeth Mitten Huong Le-Petross Isabelle Bedrosian Maria Raso OncoDaily Oncology Phase II Clinical Trial PRECISE Preoperative Radiotherapy to Elicit Critical Immune Stimulating Effects Simona Shaitelman

Immunotherapy for Melanoma: Types, Success Rate, Side Effects & More

Tom Green and Testicular Cancer: How He Went Against, How He Survived, and More

Steven O'Day: At the Forefront of Immunotherapy

Dennis Slamon was honored with the 2024 Szent-Györgyi Prize for Progress in Cancer Research

Pfizer is partnering with Patrick Dempsey in support of the American Cancer Society initiative 'Change the Odds'

Special Coverage